InnoPharmax Inc.

InnoPharmax Inc. is a specialty pharmaceutical company based in Taipei, Taiwan, founded in 1994. It develops and commercializes products for oncology and other specialties, including Bestnem (Imipenem and Cilastatin sodium solution) for infections, Gadomni (gadopentetate dimeglumine) as a contrast agent, Innomustine (bendamustine) for oncology, Immurin for immunological agents, and Inpheno tablets for rare diseases. The company also provides active pharmaceutical ingredients, including orphan drugs and MRI enhancing agents. Its pipeline includes D07001 in phase II trials for pancreatic and lung cancer and phase III for biliary tract cancer, D0191801 and D0221901 in preclinical trials for diabetes and type II diabetes, D0282102 for lymphocytic leukemia/multiple myeloma/non-Hodgkin's lymphoma, and O0242001-1, O0242001-2, O0242001-3 in preclinical trials for an MRI agent. Additionally, it offers the MUCR system and OralPas and OralPas Pro technology platforms.